ClinicalTrials.Veeva

Menu

Real-world CMV Outcomes Among Kidney Transplant Recipients in Brazil

H

Hospital do Rim e Hipertensão

Status

Invitation-only

Conditions

CMV Viremia
CMV Infection

Study type

Observational

Funder types

Other

Identifiers

NCT06263218
CCR-2023-200344

Details and patient eligibility

About

This is a single-center, non-interventional, retrospective study of data, at the level of the individual without identification, extracted from medical records of adult patients undergoing a kidney transplant procedure after 1st from January 2018 until reaching the sample size enrollment (around 500 individuals); this refers to the period of verification of individuals' eligibility for entry into the study. Individuals under strategy preemptive patients who developed CMV infection/disease within 12 months after transplantation. The data will be collected from date of transplant (including pre-transplant clinical history) until completion of at least 12 months after transplantation, or until graft loss, or recipient death or loss to follow-up, when/if applicable.

Full description

Data will be collected from medical records and will include transplant recipient characteristics, transplant-related information, CMV status, clinical outcomes, treatment patterns, healthcare resource utilization and captured on an electronic Intake Form.

Study-specific Case Report (eCRF) The sponsor will create a Statistical Analysis Plan (SAP) before collection begins of data. The eCRF system will comply with research regulations

Enrollment

500 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Received a single kidney transplant after January 1, 2018
  • Age over 18 years at time of kidney transplant.
  • It was under preemptive strategy.
  • Diagnosed with CMV infection/disease within the first 12 months after kidney transplant.
  • Follow-up information is available in medical records for at least 12 months after confirmation of CMV infection, or even loss of the allograft, death of the recipient or loss of follow-up of the receiver, when/if applicable.

Exclusion criteria

  • Diagnosed as a carrier of the human immunodeficiency virus (HIV+), hepatitis B virus and/or hepatitis C before kidney transplantation.
  • Participation in any interventional study during the period between kidney transplantation and a period of 12 months after CMV diagnosis.

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems